UK Health Regulator Completes Inspection of Lupin's Goa Plant
Mumbai-based Lupin has said the UK health regulator has completed the inspection of its Goa facility without making any critical observations. In a stock market filing, Lupin announced the successful completion of the inspection by the UK MHRA at its Goa facility in March 2018. “There were no critical or major observations in the inspections,” it added.
“We are committed to maintaining truly global quality standards at our manufacturing units. The successful inspection by UK MHRA is a meaningful development for our Goa plant,” Lupin’s Managing Director Mr. Nilesh Gupta said.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Reta10mg Retatrutide10mg 15mg 30mg Top Fat Burning Peptides Lyophilized 5mg 10mg/Vial Peptides Powder GLP-1 Retatrutide 2381089-83-2
$194.75/UNIT FOB
2026-07-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
L'Oréal UK sales hit £1.5 billion
-
Pesticide Usage in Scotland--Outdoor Vegetable Crops 2021
-
The British chemical industry is in trouble
-
British malters use malt in plant-based meat products
-
Britain considers banning solid urea
-
Triggered by the epidemic, the UK chemical market faces multiple blows
-
U.K. endorses dexamethasone in COVID-19 hours after groundbreaking data release
-
UK trials remdesivir treatment for COVID-19 as UK PM aide row rages on
-
AcetoUK acquires British fine chemicals supplier Syntor
-
UK faces 2% GDP hit by 2020 under no-deal Brexit, recession risks grow
Recommend Reading
-
NHU and Sinopec Advance Liquid Methionine Project
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Cytosine: Structure, DNA Pairing, and Role in Genetics
-
Bovine Serum Albumin (BSA): Role in Cell Culture & Laboratory Applications
-
Qatar LNG Hit by Attack: 17% Export Capacity Lost, $20 Billion Wiped Out
-
This week, the domestic anhydrous hydrogen fluoride market maintained a high-level consolidation operation (3.16-3.19)
-
China's Urea Market Shows Weak Performance (3.13-3.19)